News & Research - HBM Partners AG

NEWS & RESEARCH

Portfolio News

HBM in the News

Industry Reports

Arcutis Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares (14 KB)
4.2.2020
Download
Harmony Biosciences Secures $200 Million Debt Facility (521 KB)
27.1.2020
Download
Neurelis announces FDA approval for seizure rescue treatment VALTOCO® (52 KB)
13.1.2020
Download
Arcutis Announces ARQ-154 Program for Seborrheic Dermatitis and Enrollment of First Patient in Phase 2 Proof of Concept Clinical Trial (121 KB)
5.12.2019
Download
Arcutis Biotherapeutics Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Phase 3 Program for ARQ-151 for Plaque Psoriasis (170 KB)
24.10.2019
Download
Arcutis Announces the Completion of $94.5 million Series C Financing (179 KB)
21.10.2019
Download
UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases (54 KB)
10.10.2019
Download
Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares (19 KB)
7.10.2019
Download
Swixx signs deal to represent Alexion in Russia & announces opening of Russian operations and Swixx appointed distributor for Alexion Russia (136 KB)
1.10.2019
Download
Adrenomed completes full enrollment with 300 patients in AdrenOSS-2 trial with Adrecizumab in septic shock (123 KB)
26.9.2019
Download

<3 4 567 8 >

Das Derby der Impfstoffhersteller (163 KB)
16.11.2020
Download Read more
Gewinne aus dem Labor (310 KB)
01.11.2020
Download Read more
Andreas Wicki, CEO HBM Healthcare Investments AG “The importance of biotech as the backbone of innovation of the pharma industry is growing all the time.” (156 KB)
18.08.2020
Download Read more
«Bedeutung von Biotech als Innovations-Rückgrat der Pharma-Industrie nimmt stetig zu» (196 KB)
18.08.2020
Download Read more
Biotech im Hoch: Nicht alle Healthcare-Unternehmen kommen gleich durch die Corona-Krise (499 KB)
25.07.2020
Download Read more
Virus eröffnet Anlage-Chancen (100 KB)
2.4.2020
Download Read more
Pharmaprofis kaufen keine Corona-Aktien (123 KB)
1.4.2020
Download Read more
Der Bedarf der Pharmakonzerne nach neuen Medikamenten ist ungestillt - Interview Dr. Andreas Wicki (302 KB)
6.11.2019
Download Read more
Investing in biotechnology - a lucrative approach (304 KB)
1.9.2019
Download Read more
Investieren in die Biotechnologie – ein aktiver Ansatz zahlt sich aus (4594 KB)
1.9.2019
Download Read more
Interview with Andreas Wicki (351 KB)
Download Read more
Interview with Ivo Staijen (263 KB)
17.7.2019
Download Read more
Biotech-Unternehmen schwimmen im Geld (309 KB)
25.5.2019
Download Read more
„Ungebremste Innovationskraft" (628 KB)
1.5.2019
Download Read more
Unbridled Capacity for Innovation (101 KB)
1.5.2019
Download Read more
Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)
23.1.2019
Download Read more
Investing in listed private equity – more than just an alternative (197 KB)
23.1.2019
Download Read more
Kleine Hersteller, grosses Potenzial (1007 KB)
1.1.2019
Download Read more
Investieren in den Gesundheitssektor – Chancen für den Anleger (487 KB)
4.11.2018
Download Read more
A Biotechnology Bonanza (397 KB)
1.10.2018
Download Read more

Trends in New Drug Approvals

Report covers new drugs approved by US FDA. The latest report as well as a list of new drug approvals since 2003 are available for download.

Analysis of FDA Approvals 2018 and Previous Years (1147 KB)
Download
FDA Approved NMEs 2003-2018 (86 KB)
Download

HBM Pharma/Biotech M&A Report

HBM Partners carries out an ongoing analysis of all trade sales of public and private US and European biotech and pharma companies. The latest HBM Pharma/Biotech M&A Report as well as information on M&A transactions since 2005 are available for download:

Credits

Sitemap

Arcutis Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares (14 KB)

Harmony Biosciences Secures $200 Million Debt Facility (521 KB)

Neurelis announces FDA approval for seizure rescue treatment VALTOCO® (52 KB)

Arcutis Announces ARQ-154 Program for Seborrheic Dermatitis and Enrollment of First Patient in Phase 2 Proof of Concept Clinical Trial (121 KB)

Arcutis Biotherapeutics Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Phase 3 Program for ARQ-151 for Plaque Psoriasis (170 KB)

Arcutis Announces the Completion of $94.5 million Series C Financing (179 KB)

UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases (54 KB)

Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares (19 KB)

Swixx signs deal to represent Alexion in Russia & announces opening of Russian operations and Swixx appointed distributor for Alexion Russia (136 KB)

Adrenomed completes full enrollment with 300 patients in AdrenOSS-2 trial with Adrecizumab in septic shock (123 KB)

Das Derby der Impfstoffhersteller (163 KB)

Gewinne aus dem Labor (310 KB)

Andreas Wicki, CEO HBM Healthcare Investments AG “The importance of biotech as the backbone of innovation of the pharma industry is growing all the time.” (156 KB)

«Bedeutung von Biotech als Innovations-Rückgrat der Pharma-Industrie nimmt stetig zu» (196 KB)

Biotech im Hoch: Nicht alle Healthcare-Unternehmen kommen gleich durch die Corona-Krise (499 KB)

Virus eröffnet Anlage-Chancen (100 KB)

Pharmaprofis kaufen keine Corona-Aktien (123 KB)

Der Bedarf der Pharmakonzerne nach neuen Medikamenten ist ungestillt - Interview Dr. Andreas Wicki (302 KB)

Investing in biotechnology - a lucrative approach (304 KB)

Investieren in die Biotechnologie – ein aktiver Ansatz zahlt sich aus (4594 KB)

Interview with Andreas Wicki (351 KB)

Interview with Ivo Staijen (263 KB)

Biotech-Unternehmen schwimmen im Geld (309 KB)

„Ungebremste Innovationskraft" (628 KB)

Unbridled Capacity for Innovation (101 KB)

Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)

Investing in listed private equity – more than just an alternative (197 KB)

Kleine Hersteller, grosses Potenzial (1007 KB)

Investieren in den Gesundheitssektor – Chancen für den Anleger (487 KB)

A Biotechnology Bonanza (397 KB)

Trends in New Drug Approvals

Analysis of FDA Approvals 2018 and Previous Years (1147 KB)

FDA Approved NMEs 2003-2018 (86 KB)

HBM Pharma/Biotech M&A Report

Biopharma M&A Update H1 2019 and Potential Implications of Mega Mergers for Smaller Biopharma Deal Making (470 KB)

HBM Pharma / Biotech M&A Report 2020 (1299 KB)

Pharma / Biotech M&A Transctions 2005-2019 (119 KB)